Abstract
Coronary heart disease (CHD) is an important health problem in the United States, responsible for more than 503,000 deaths annually [1]. It has traditionally been underestimated in women, even though CHD is the single leading cause of death and a significant cause of morbidity in female patients. In fact, CHD is now estimated to account for more than 236,000 deaths among women each year, resulting in billions of dollars in health care expenditures [2]. Furthermore, it is estimated that 1 in 2 women will die of heart disease or stroke, compared with 1 in 25 who will eventually die of breast cancer [3], Unfortunately, women are not aware of this overwhelming risk presented by CHD. In a recent national survey by the American Heart Association, only 34% of women spontaneously identified CHD as the leading cause of death in women [3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
US Department of Health and Human Services, Centers for Disease Control and Prevention. Chronic diseases and their risk factors: The nation’s leading causes of death. National Center for Chronic Disease Prevention and Health Promotion 1999.
American Heart Association. Women, heart disease, and stroke statistics. American Heart Association 2000.
American Heart Association. Women, heart disease and stroke: Survey highlights and comparison, 2000. American Heart Association 2001.
Barrett-Connor E. Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys lecture. Circulation 1997; 95:252–64.
National Institutes of Health. The Framingham Heart Study. Available at: http://www.nhlbi.nih.gov/_about/framingham. Accessed June 21, 2001.
Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: The Framingham Study. N Engl J Med 1985; 313:1038–43.
Nurses’ Health Study home page. Available at: http://www.channing.harvard.edu/nhs. Accessed June 21, 2001.
Belanger CF, Hennekens CH, Rosner B, Speizer FE. The Nurses’ Health Study. Am J Nurs 1978; 78:1039–40.
Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease in U.S. women. N Engl J Med 1985; 313:1044–49.
Petitti DB. Hormone replacement therapy and heart disease prevention: Experimentation trumps observation [commentary].JAMA1998; 280:650–52.
Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20:47–63.
Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016–37.
Sullivan JM. Estrogen replacement therapy. Circulation. 1996; 94(11):2699–2702.
Rossouw JE. Estrogens for prevention of coronary heart disease: Putting the brakes on the bandwagon. Circulation 1996:94; 2982–85.
Matthews KA, Kuller CN, Wing RR, Mailahan EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996; 143:971–78.
Coronary Drug Project Research Group. The Coronary Drug Project design, methods, and baseline results. Circulation 1973; 47(Suppl.3):I1-I50.
Coronary Drug Project Research Group. The Coronary Drug Project: Initial findings leading to modification of its research protocol. JAMA 1970; 214:1303–13.
Coronary Drug Project Research Group. The Coronary Drug Project: Findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA 1973; 226:652–57.
Hulley S, Grady D, Bush T, et al for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605–13.
Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343:522–29.
The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19:61–109.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Johnson, K.C. (2002). Hormone Replacement and Cardiovascular Disease. In: Lobo, R.A., Crosignani, P.G., Paoletti, R., Bruschi, F. (eds) Women’s Health and Menopause. Medical Science Symposia Series, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1061-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1061-1_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5375-1
Online ISBN: 978-1-4615-1061-1
eBook Packages: Springer Book Archive